The person shown here is a basic user of this site. He or she may be contacted directly for language-related services.
|
Working languages: English to German
| Dr. Eva Mueller
Scientist who understands your projects
NA Local time: 11:52 CET (GMT+1)
Native in: German  | |
Freelancer,  Verified site user | | Specializes in: | | Biology (-tech,-chem,micro-) | Science (general) |
| Also works in: | | Biology (-tech,-chem,micro-) | Medical (general) |
More Less | | Questions asked: 4 | Sample translations submitted: 1 | English to German: FOCUSED COMPOUND LIBRARIES FOR RECEPTOR DEORPHANING | Source text - English
FOCUSED COMPOUND LIBRARIES FOR RECEPTOR DEORPHANING
As drug discovery targets are concerned, no group is more enticing than the orphan receptors. By their very nature of acting at the interface between cellular function and the surrounding environment, cell-surface receptors, in general, are obvious choices as drug discovery targets. They are involved in nearly all physiological processes and are easily accessible by small-molecule drugs. Orphan receptors are gene products identified as receptors based on sequence or structural homology that have no identified ligands. They number in the hundreds and belong to receptor classes that historically have made very successful drug targets. As a result, identification of selective ligands for these receptors with the aim of understanding function or evaluating clinical potential is a major goal of many researchers.
G-protein coupled receptors (GPCRs) are the largest group of transmembrane receptors and regulate many pathophysiological processes1. Approximately 45% of marketed drugs target GPCRs2 and are utilized to treat diverse diseases including pain, asthma, schizophrenia, depression, peptic ulcers, allergies and hypertension3. GPCRs share a characteristic topology, consisting of seven alpha-helical transmembrane domains and are readily identified from DNA sequence information. The human genome contains 750 putative GPCRs3. While approximately half of these are olfactory or visual receptors, the remaining are potential targets for drug discovery. Ligands are known for many of these receptors, but approximately 150 have no known ligand or function (see figure)3. Given the previous success in developing drugs against this class of targets, identifying ligands for or “deorphaning” these GPCRs to gain incite into their function and to develop new therapeutic agents is of great interest.
…
| Translation - German
FOKUSSIERTE SUBSTANZBIBLIOTHEKEN FÜR DAS „DEORPHANING“ VON REZEPTOREN
Was Targets für die Wirkstoffsuche betrifft, so ist keine Gruppe verlockender, als die der Orphan Rezeptoren („verwaiste“ Rezeptoren). Allein schon durch die Tatsache, dass diese Moleküle an der Schnittstelle zwischen zellulären Funktionen und dem umgebenden Milieu agieren, sind Zelloberflächenrezeptoren im allgemeinen naheliegende Kandidaten für Wirkstofftargets. Sie sind an nahezu allen physiologischen Prozessen beteiligt und für small-molecule-Wirkstoffe leicht zugänglich. Orphan Rezeptoren sind Genprodukte, die aufgrund von Sequenz- oder strukturellen Homologien als Rezeptoren identifiziert werden konnten, deren Liganden jedoch nicht bekannt sind. Ihre Zahl geht in die Hunderte und sie gehören zu Rezeptorklassen, aus denen in der Vergangenheit sehr erfolgreiche Wirkstofftargets hervorgegangen sind. Dies ist der Grund dafür, dass die Identifikation selektiver Liganden für diese Rezeptoren, mit der Absicht deren Funktion zu verstehen und deren klinisches Potenzial zu ermitteln, eines der größten Ziele vieler Forscher ist.
G-Protein gekoppelte Rezeptoren (GPCRs) stellen die größte Gruppe an transmembranalen Rezeptoren dar und sie sind an der Regulation vieler pathophysiologischer Prozesse beteiligt1. Ungefähr 45% aller vermarkteten Medikamente sind gegen GPCRs gerichtet2. Sie werden zur Behandlung der unterschiedlichsten Erkrankungen eingesetzt, einschließlich Schmerz, Asthma, Schizophrenie, Depressionen, peptischer Ulkus, Allergien und Hochdruck3. GPCRs ähneln sich in ihrer charakteristischen, aus sieben alpha-helikalen transmembranalen Domänen bestehenden, räumlichen Struktur, und können einfach anhand von DNA-Sequenzinformationen identifiziert werden. Das menschliche Genom enthält 750 putative GPCRs3. Ungefähr die Hälfte davon sind olfaktorische und visuelle Rezeptoren, die verbleibenden stellen potentielle Targets für die Wirkstoffsuche dar. Während für viele dieser Rezeptoren Liganden bekannt sind, gibt es ca. 150, von denen man weder den Liganden noch die Funktion kennt (siehe Abbildung)3. Nimmt man die vorangegangenen Erfolge bei der Entwicklung von Medikamenten gegen diese Klasse von Targetmolekülen, dürfte die Identifikation von Liganden für diese GPCRs bzw. deren „Deorphaning“ (den Waisenstatus aufheben) von größtem Interesse sein, um Einblick in deren Funktion zu gewinnen aber auch um neue Medikamente zu entwickeln.
...
|
More Less | | Other - British Council | | Years of translation experience: 2. Registered at ProZ.com: Aug 2003. | | N/A | | N/A | | N/A | | Excel, Word 2000, Powerpoint, SDL TRADOS | | http://www.lifescience-texte.de | | About me * Life sciences
* Biotechnology
* Biology
* Molecular biology
* Genetics
* Biochemistry
* Bioinformatics
* Drug discovery and development
* Pharma
* Medicine
SERVICES
* Translating
* Proofreading
* Abstracting
SCIENTIFIC BACKGROUND
Translating scientific texts is not just knowing the technical terms, but requires most of all an active scientific understanding. Only someone who grasps the meaning of a text is able to render it correctly in another language. A degree in biology and many years work experience as a researcher provide me with broad subject-matter knowledge necessary to understand a wide range of scientific topics, but also with specialist knowledge of German and English life science terminology and vocabulary.
BROAD RANGE OF TECHNICAL EXPERTISE
I regularly work with biotech and pharma companies and universities. Therefore, I am well informed about many distinct areas of the life sciences and numerous innovative approaches and technologies. Related to the various working areas of my customers I have already dealt with a number of very different topics, including bioinformatics, immunology, nano-biotechnology, drug development, or array technologies.
LANGUAGE AND WRITING SKILLS
Through a combination of special courses, a period of work in the US and writing of numerous scientific texts in English I gained advanced-level English. Besides translating I also work as a science writer in Germany. Therefore, I am familiar with the specific writing styles of, for example, scientific publications and product manuals but also of advertising texts and texts for public relations with a scientific content.
CUSTOMERS
Baxter BioScience, BIOMOL GmbH, Epigenomics AG, ActinoDrug Pharmaceuticals GmbH, atugen AG, Stonecleaner AG, |
|
Keywords: biotechnology, pharma, medicine, biology, life science, molecular biology, cell biology, genetics, biochemistry, bioinformatics, drug-discovery, nano-technology, immunology, cancer, drug-development, translation, proofreading, abstracting, summarizing, German, Germany, English |
The translation workplace 
Expertise